论文部分内容阅读
目的分析33例慢性乙型肝炎(CHB)患者应用聚乙二醇干扰素治疗的效果。方法33例CHB患者均采用聚乙二醇干扰素180μg皮下注射,每周1次,连续48周。检测治疗前后HBsAg定量、HBV DNA定量、CD4+T细胞及CD8+T细胞和调节性T细胞(Treg细胞)百分率,分析治疗前HBsAg、HBV DNA、免疫状态与HBsAg阴转的关系。结果 CD4+T细胞百分率阴转组高于未阴转组[(41.09±10.25)%vs.(31.86±7.84)%](P<0.05);CD8+T细胞百分率阴转组低于未阴转组[(20.86±5.47)%vs.(28.38±6.46)%](P<0.05)。HBsAg 1-150IU/ml组阴转率为58.3%,高于151-500IU/ml组的11.1%和501-2500IU/ml组的8.3%(P<0.05)。CHB患者CD4+T细胞百分率与HBsAg水平呈负相关(P<0.05)。结论 HBsAg<500IU/ml及处于非免疫耐受状态可作为应用聚乙二醇干扰素抗病毒治疗的优选人群。
Objective To analyze the effect of pegylated interferon on 33 patients with chronic hepatitis B (CHB). Methods 33 CHB patients were injected subcutaneously with peginterferon 180μg once a week for 48 weeks. The levels of HBsAg, HBV DNA, CD4 + T cells, CD8 + T cells and regulatory T cells (Treg cells) were measured before and after treatment. The relationship between HBsAg, HBV DNA and the status of HBsAg was analyzed before treatment. Results The percentages of CD4 + T cells in the negative group were significantly higher than those in the negative group ([41.09 ± 10.25]% vs (31.86 ± 7.84)%] (P <0.05) Group [(20.86 ± 5.47)% vs (28.38 ± 6.46)%] (P <0.05). The negative conversion rate for HBsAg 1-150 IU / ml was 58.3%, higher than 11.1% for the 151-500 IU / ml group and 8.3% for the 501-2500 IU / ml group (P <0.05). The percentage of CD4 + T cells in CHB patients was negatively correlated with HBsAg level (P <0.05). Conclusion HBsAg <500IU / ml and in non-immune tolerant state can be used as the preferred group of patients treated with peginterferon.